Yong-Oon Ahn
Overview
Explore the profile of Yong-Oon Ahn including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
38
Citations
729
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Jeong D, Lee D, Kim N, Choi S, Kim K, Kim S, et al.
Leuk Res
. 2019 Nov;
87:106249.
PMID: 31666185
No abstract available.
12.
Jeong D, Lee D, Kim N, Choi S, Kim K, Kim S, et al.
Leuk Res
. 2019 Aug;
85:106210.
PMID: 31470354
No abstract available.
13.
Hwang S, Kim S, Nam Y, Kim J, Kim S, Ahn Y, et al.
Leuk Res
. 2019 Aug;
84:106190.
PMID: 31377458
Chronic myelomonocytic leukemia (CMML) typically shows monocytosis in the peripheral blood (PB), which must be differentiated from reactive monocytosis. To determine the clonality of CMML, we performed molecular and cytogenetic...
14.
Park H, Ahn Y, Kim T, Kim S, Kim S, Lee Y, et al.
Cytotherapy
. 2019 Apr;
21(6):603-611.
PMID: 31010733
Background: Treatment with tyrosine kinase inhibitors (TKIs) has improved the outcomes for patients with non-small cell lung cancer (NSCLC) harboring targetable driver mutations. However, acquired resistance to TKIs invariably develops...
15.
Kang S, Keam B, Ahn Y, Park H, Kim M, Kim T, et al.
Oncoimmunology
. 2018 Dec;
8(1):e1515057.
PMID: 30546955
Major histocompatibility complex (MHC) class I downregulation is the primary immune evasion mechanism associated with failure in anti-PD-1/PD-L1 blockade therapies for cancer. Here, we examined the role of MEK signaling...
16.
Kim S, Kim T, Kim D, Kim S, Kim M, Ahn Y, et al.
Cancer Res Treat
. 2018 Oct;
51(3):951-962.
PMID: 30309221
Purpose: Amplified mesenchymal-epithelial transition factor, MET, is a receptor tyrosine kinase (RTK) that has been considered a druggable target in non-small cell lung cancer (NSCLC). Although multiple MET tyrosine kinase...
17.
Lee J, Choi J, Ahn Y, Kim T, Heo D
Cell Immunol
. 2018 Mar;
327:21-25.
PMID: 29499908
Extranodal natural killer (NK)/T-cell lymphoma is an aggressive malignant disease that is associated with Epstein-Barr viral (EBV) infection. To date, the mechanism of viral entry into NK cells remains uncertain....
18.
Ock C, Kim S, Keam B, Kim S, Ahn Y, Chung E, et al.
Oncotarget
. 2017 Dec;
8(58):97920-97927.
PMID: 29228662
Programmed death-ligand 1 (PD-L1) expression is regarded as a predictive marker for anti-PD-1/PD-L1 therapy. The purpose of study was to explore the changes in PD-L1 expression in head and neck...
19.
Sim S, Kim S, Kim T, Jeon Y, Jeong Nam S, Ahn Y, et al.
Am J Pathol
. 2017 Mar;
187(5):980-986.
PMID: 28284718
Inhibition of the Janus kinase (JAK)-STAT pathway has been implicated as a treatment option for extranodal natural killer/T-cell lymphoma, nasal type (NTCL). However, JAK-STAT pathway alterations in NTCL are variable,...
20.
Alsuliman A, Muftuoglu M, Khoder A, Ahn Y, Basar R, Verneris M, et al.
Blood
. 2016 Nov;
129(6):740-758.
PMID: 27821506
The establishment of long-lived pathogen-specific T cells is a fundamental property of the adaptive immune response. However, the mechanisms underlying long-term persistence of antigen-specific CD4 T cells are not well-defined....